SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β(1)-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders.
Authors: Turilli-Ghisolfi ES, Støve SI, Huertas O, Kråkenes TA, Teigen K, Panigone S, Medori R
Journal: Frontiers in pharmacology
psychopharmacology
mental health
open access